Asgard Therapeutics’ study published in Science showing proof-of-concept and strong anti-tumor responses via in vivo cell reprogramming with lead program AT-108
- Study of Asgard’s new cancer immunotherapy modality demonstrates potent anti-tumor effects by turning tumor cells against themselves
- New data “paves the way for first-in-human trials” of lead program AT-108, which is undergoing CMC development for GMP manufacturing
- AT-108 is an off-the-shelf gene therapy that induces an immune response tailored against each unique patient’s cancer
Lund, Sweden, 5 September 2024 – Asgard Therapeutics, a privately held biotech company pioneering in vivo direct cell reprogramming for cancer immunotherapy, today announces the publication of key proof-of-concept data supporting its lead program, AT-108, in the high-impact, peer-reviewed journal, Science[1]. Novel data shows that AT-108 reprograms tumor cells, directly within the immunosuppressed tumor microenvironment, into an immunogenic cell fate, which mounts strong anti-tumor, antigen-specific responses and durable tumor shrinkage even upon metastatic rechallenge.
